Medincell Sa Stock Performance

MDCLF Stock  USD 34.39  27.41  392.69%   
MedinCell holds a performance score of 10 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of -7.39, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning MedinCell are expected to decrease by larger amounts. On the other hand, during market turmoil, MedinCell is expected to outperform it. Use MedinCell SA total risk alpha, and the relationship between the variance and rate of daily change , to analyze future returns on MedinCell SA.

Risk-Adjusted Performance

Fair

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in MedinCell SA are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile essential indicators, MedinCell reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Begin Period Cash Flow47.1 M
Total Cashflows From Investing Activities-316 K
  

MedinCell Relative Risk vs. Return Landscape

If you would invest  698.00  in MedinCell SA on October 28, 2025 and sell it today you would earn a total of  2,741  from holding MedinCell SA or generate 392.69% return on investment over 90 days. MedinCell SA is currently producing 6.4376% returns and takes up 50.2792% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than MedinCell, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days.
  Expected Return   
       Risk  
Assuming the 90 days horizon MedinCell is expected to generate 68.18 times more return on investment than the market. However, the company is 68.18 times more volatile than its market benchmark. It trades about 0.13 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.07 per unit of risk.

MedinCell Target Price Odds to finish over Current Price

The tendency of MedinCell Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 34.39 90 days 34.39 
near 1
Based on a normal probability distribution, the odds of MedinCell to move above the current price in 90 days from now is near 1 (This MedinCell SA probability density function shows the probability of MedinCell Pink Sheet to fall within a particular range of prices over 90 days) .
Assuming the 90 days horizon MedinCell SA has a beta of -7.39. This indicates as returns on its benchmark rise, returns on holding MedinCell SA are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, MedinCell is expected to outperform its benchmark. In addition to that MedinCell SA has an alpha of 6.4453, implying that it can generate a 6.45 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   MedinCell Price Density   
       Price  

Predictive Modules for MedinCell

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as MedinCell SA. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
1.7234.393,473
Details
Intrinsic
Valuation
LowRealHigh
1.1422.863,462
Details
Naive
Forecast
LowNextHigh
0.6934.6184.89
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
-5.899.2624.42
Details

MedinCell Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. MedinCell is not an exception. The market had few large corrections towards the MedinCell's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold MedinCell SA, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of MedinCell within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
6.45
β
Beta against Dow Jones-7.39
σ
Overall volatility
3.37
Ir
Information ratio 0.12

MedinCell Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of MedinCell for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for MedinCell SA can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
MedinCell SA is way too risky over 90 days horizon
MedinCell SA appears to be risky and price may revert if volatility continues
The company reported the revenue of 4.09 M. Net Loss for the year was (24.81 M) with profit before overhead, payroll, taxes, and interest of 4.09 M.
MedinCell SA has accumulated about 34.39 M in cash with (21.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.38.
Roughly 48.0% of the company outstanding shares are owned by corporate insiders
Latest headline from thelincolnianonline.com: Simplicity Wealth LLC Has 3.56 Million Holdings in Merck Co., Inc. MRK

MedinCell Fundamentals Growth

MedinCell Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of MedinCell, and MedinCell fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on MedinCell Pink Sheet performance.

About MedinCell Performance

By analyzing MedinCell's fundamental ratios, stakeholders can gain valuable insights into MedinCell's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if MedinCell has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if MedinCell has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception mdc-ANG for CNS related treatments mdc-ELK for depression and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. Medincell is traded on OTC Exchange in the United States.

Things to note about MedinCell SA performance evaluation

Checking the ongoing alerts about MedinCell for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for MedinCell SA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
MedinCell SA is way too risky over 90 days horizon
MedinCell SA appears to be risky and price may revert if volatility continues
The company reported the revenue of 4.09 M. Net Loss for the year was (24.81 M) with profit before overhead, payroll, taxes, and interest of 4.09 M.
MedinCell SA has accumulated about 34.39 M in cash with (21.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.38.
Roughly 48.0% of the company outstanding shares are owned by corporate insiders
Latest headline from thelincolnianonline.com: Simplicity Wealth LLC Has 3.56 Million Holdings in Merck Co., Inc. MRK
Evaluating MedinCell's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate MedinCell's pink sheet performance include:
  • Analyzing MedinCell's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MedinCell's stock is overvalued or undervalued compared to its peers.
  • Examining MedinCell's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating MedinCell's management team can have a significant impact on its success or failure. Reviewing the track record and experience of MedinCell's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of MedinCell's pink sheet. These opinions can provide insight into MedinCell's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating MedinCell's pink sheet performance is not an exact science, and many factors can impact MedinCell's pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for MedinCell Pink Sheet analysis

When running MedinCell's price analysis, check to measure MedinCell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MedinCell is operating at the current time. Most of MedinCell's value examination focuses on studying past and present price action to predict the probability of MedinCell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MedinCell's price. Additionally, you may evaluate how the addition of MedinCell to your portfolios can decrease your overall portfolio volatility.
CEOs Directory
Screen CEOs from public companies around the world
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Commodity Directory
Find actively traded commodities issued by global exchanges
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk